chinese biopharmaceutical companies are accelerating their overseas expansion, with emerging markets such as asean and the middle east becoming important destinations
2024-09-01
한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina
original title: asean, the middle east and other emerging markets become important destinations (lead)
chinese biopharmaceutical companies are accelerating their overseas expansion (topic)
beijing daily (reporter yuan lu) yesterday, the first biopharmaceutical industry development linkong conference was held in the beijing daxing international airport linkong economic zone. the reporter learned from the conference that in the past five years, the global pharmaceutical market has grown at an average annual compound growth rate of nearly 4%. with the acceleration of the reconstruction and reengineering of the global pharmaceutical industry chain, my country's innovative drugs have entered a period of explosive results, and the pace of biopharmaceutical companies' "going overseas" has also accelerated significantly.
my country's pharmaceutical companies are increasing their efforts in new drug research and development, and a number of domestic innovative drugs are reaping the fruits of their efforts. meng dongping, secretary of the party committee of the china chamber of commerce for import and export of medicines and health products, presented a set of data at the meeting - in the first half of this year, 44 new drugs were approved for marketing in china for the first time, including 23 class 1 innovative drugs; in 2023, my country will approve 40 class 1 innovative drugs for marketing, which is almost the sum of the number approved in the previous five years.
meng dongping said that with the continuous breakthroughs in cutting-edge technologies, the continuous improvement of new drug production and manufacturing technology capabilities, and the increasing speed of industrialization and clinical application transformation, my country's innovative drug research and development has shown an unprecedentedly active trend.
in the innovative drug industry, especially the biopharmaceutical industry, which is booming, local companies are also actively embracing the international market through both "going overseas on their own" and "borrowing a boat to go overseas".
"going overseas independently" means that chinese pharmaceutical companies independently conduct clinical trials overseas, then apply for listing, and sell after approval. meng dongping introduced that since beigene's zanubrutinib first "knocked on" the u.s. food and drug administration (fda) in 2019, as of now, my country has had 7 innovative drug varieties approved for marketing by the u.s. fda, including 2 monoclonal antibody drugs and 1 car-t cell therapy.
"borrowing a boat to go to sea" means that chinese pharmaceutical companies sell the overseas or global rights of their products to overseas companies, and the overseas companies are responsible for subsequent clinical development, listing application, production and sales. reporters learned that in 2023, the number of china's innovative drug rights authorization transfer transactions was close to 70, and projects in the preclinical research and development stage accounted for nearly 40%, and both the transaction amount and down payment set new records.
despite the downward pressure on the global economy, the demand for the global medical market is still growing. according to reports, the global pharmaceutical market has achieved an average annual compound growth rate of nearly 4% in the past five years.
"the global medical market is expanding rapidly, creating opportunities for chinese medical companies to go overseas." meng dongping said that emerging markets such as asean countries, the middle east, and latin america are becoming important target markets for the entire chinese pharmaceutical industry to go overseas.
it is worth noting that a large number of chinese medicine products are going overseas and entering the mainstream european and american markets. meng dongping said that my country's chinese herbal medicine pieces, plant extracts, etc. have spread to 196 countries and regions, of which 29 countries have established laws and regulations for traditional medicine. at the same time, my country has signed cooperation agreements on traditional chinese medicine with 43 foreign governments, regions and international organizations.
beigene, sinovac, minhai bio... the reporter noticed that beijing companies frequently appeared among the biopharmaceutical companies actively embracing the international market. the strong momentum of enterprises to "go global" is inseparable from a strong industrial foundation. according to reports, the beijing daxing international airport airside economic zone is building a biopharmaceutical industry cluster worth hundreds of billions of yuan, and key projects such as the international biopharmaceutical park, the international regenerative medicine industrial park, the international medical device industrial park, and the sinopharm supply chain center are gradually being put into operation.
source: beijing daily
